Explore every episode of the podcast MedInsights Unleashed

In this MedInsights Unleashed episode, Dr. Ari Rosenberg from University Chicago Medical Center, delves into the complexities and advancements in the treatment of head and neck cancers. Despite the recurrence and resistance these cancers often develop, immunotherapy has marked a significant breakthrough, especially in releasing the immune system's brakes. Although its introduction in early-stage cancer remains elusive, ongoing trials indicate potential when combined with chemotherapy pre-treatment. Dr. Rosenberg highlights innovative therapies, including targeting HPV-specific cancer proteins and antibody drug conjugates, which hold promise in enhancing treatment efficacy. These cutting-edge strategies aim to outmaneuver resistant cancer cells, providing hope for improved survival rates.

In this episode Professor Philippe Merle explains the interplay between chronic liver conditions and the development of HCC. The conversation highlights the significance of early diagnosis and consistent patient monitoring to catch the disease in its nascent stages. Professor Merle also discusses the evolving landscape of HCC treatments, including innovative therapies and the benefits of a multidisciplinary medical team in managing complex cases.

In this episode of Med Insights Unleashed, hosts Zee and John welcome Michael Staehler MD Ph.D, Professor of Urology at the University of Munich and Head the Interdisciplinary Center for Renal Tumors at Ludwig-Maximilian University, Munich. to discuss renal cell carcinoma. He explains how patient selection and managing side effects, including sexual dysfunction, play critical roles in effective cancer treatment. The conversation also delves into the balance between drug efficacy and patient experience, highlighting the importance of patient communication and personalized care in clinical practice.

In this episode, hosts Zahra and John welcome Dr. Ari Rosenberg from University Chicago Medical Center, to explore head and neck cancer, a disease affecting nearly 900,000 people annually worldwide. Dr. Rosenberg delves into the complexities of diagnosing and treating cancers in the head and neck region. The discussion highlights the significant role of HPV, particularly in oropharynx cancers, and the promising impact of HPV vaccination. Emphasizing early detection, Dr. Rosenberg also shares insights on the importance of regular dental check-ups in identifying potential cancerous lesions.

In this episode, Professor Escudier from Gustave Roussy, a major cancer center in Paris France, discusses the advances in kidney cancer treatment over the past 30 years. Professor Escudier discusses the significance of the Keynote 564, the first positive trial in adjuvant renal cell cancer. He explains how these findings impact first-line treatment decisions for metastatic kidney cancer. He discusses the differences between cure, complete response and the role of the MDT, clinical and pathological biomarkers in treatment selection. Professor Escudier especially covers the questions that he patient should their doctors concerning their renal cancer and defines the differences between Clear Cell and Non-Clear Cell renal cancer treatment outcomes and expectations.

In this episode, Dr. Ariel Goldman and Lewis Collins discuss the advancements in hip fracture care. They highlight the urgent need for timely surgical intervention and reveal how these practices have successfully reduced complications and mortality rates. Focusing on the aging population and osteoporosis, they stress the importance of understanding risk factors and prevention. They compare exercise forms, such as Tai Chi, to other physical therapy methods in preventing hip fractures and emphasize the benefits of weight-bearing exercises. Tai Chi, in particular, is highlighted for its role in increasing strength and bone density, contributing to early treatment success. This episode provides valuable insights into the benefits of immediate care, pain management solutions like nerve blocks, and the role of research in improving patient outcomes globally.

In this episode, Prof Galle, a hepatologist and Professor of Medicine at University Medical Center Mainz, Germany, has an in-depth conversation with co-hosts Zee and John of MedInsights Unleashed on the late breaking data, CM9DW, presented at ASCO 2024. The episode covers:

- **Cutting-Edge Therapies:** Explore the transformation in HCC treatment from surgery and transplantation to the latest immunotherapies. Discover how IV therapies demonstrate superior efficacy and manageable toxicity compared to oral options.

- **Checkmate 9DW Trial Insights:** Get an in-depth analysis of the pivotal Checkmate 9DW trial, comparing immunotherapy agents (Nivolumab and Ipilimumab) with tyrosine kinase inhibitors (lenvatinib or sorafenib). Learn about the trial's diverse patient population and the critical role of alpha fetoprotein as a prognostic marker.

- **Combination vs. Monotherapy:** Hear why combination therapies are setting new benchmarks in complete response rates and overall survival, offering new hope for liver cancer patients.

- **Multidisciplinary Approach:** Understand the crucial role of multidisciplinary teams in navigating complex decisions involving liver transplantation, intra-arterial therapies, and systemic treatments.

- **Patient Management and Outcomes:** Discover the significance of early side-effect management and patient education in improving long-term outcomes, reducing treatment visits, and enhancing quality of life.

Professor Markus Peck-Radosavljevic, MD MBA, is Professor of Medicine and Chairman at the Department of Internal Medicine & Gastroenterology (IMuG) at Klinikum Klagenfurt in Austria. A renowned gastroenterologist and hepatologist, he discusses the importance of understanding risks in medical treatments, clear communication, and considering patient preferences in treatment decisions. Professor Peck addresses challenges in patient selection for clinical trials and the impact on access to innovative treatments. Professor Peck also emphasizes the role of second opinions, the importance of trust in the patient-physician relationship, and the expertise required for state-of-the-art care. He touches on the complexities of information overload and the emerging role of artificial intelligence in healthcare decision-making.

This podcast episode focuses on radioembolization and its implications in liver cancer treatment. Professor Edward Kim, Director of Interventional Oncology at Mount Sinai Health Systems, provides insights into the use of radioembolization, a minimally invasive procedure that delivers radiation directly to liver tumors. He discusses its utilization across different stages of primary liver cancer, from curative intent therapies in early stages to palliative care in advanced stages. Professor Kim emphasizes the importance of a multidisciplinary approach in liver cancer care, where different specialists collaborate to determine the best treatment options for each patient. The episode also touches on the combination of radioembolization with systemic therapy, ongoing trials and studies, as well as the challenges and opportunities in liver cancer treatment. Overall, this episode offers valuable information and hope for liver cancer patients and their caregivers.

This transcript explores the challenges faced by both physicians and patients in accessing treatment.

Professor Vogel discusses the differences in treatment access between Germany and Canada, having experienced both healthcare systems. He highlights the restrictive criteria for liver transplantation in Germany and the limited availability of certain therapies in Canada, particularly for rare cancers like cholangiocarcinoma. The discussion delves into the ethical implications of withholding potentially life-saving treatments and the need for a more streamlined and patient-centered approach to reimbursement. Financial toxicity is also examined, as well as the role of patient advocacy in driving change and ensuring timely access to treatment.

The transcript concludes with a call to action for patients and healthcare professionals to advocate for improved access to the right treatment at the right time.

MedInsights Unleashed is an exciting new podcast aimed at providing valuable information and insights for patients and healthcare professionals.

In this first episode, hosts Zahra and John are joined by Professor Arndt Vogel to discuss key data from the adjuvant setting of liver cancer. They talk about the challenges of liver cancer treatment, the high mortality rate associated with the disease, and the progress made in recent years.

Professor Vogel provides an overview of the IMbrave 050 study, which was designed to investigate the efficacy of an adjuvant treatment combination of the checkpoint inhibitor atezolizumab and the targeted therapy bevacizumab in delaying or preventing recurrence compared with active surveillance. The study shows promising results in terms of improved recurrence-free survival, but longer follow up is needed to determine its impact on overall survival. The conversation also touches on the safety profile of the treatment and the importance of multidisciplinary teams in decision-making.

Trailer for MedInsights Unleashed with Zee and John, starring co-hosts Zahra Ramji (aka Zee) and John Collins

In their debut episode, John Collins and Zahra, also known as Zee, introduce themselves and their backgrounds in the pharmaceutical industry and healthcare. With a focus on filling the void between physicians and patients, they share their passion for improving patient outcomes, particularly in underserved areas like liver cancer. John draws parallels from his experience as an EMS first responder, emphasizing the importance of rapid knowledge transfer in saving lives. Zahra discusses her work in clinical trials and oncology, highlighting the desire to make a tangible difference in patients' lives. Together, they embark on a journey through the MedInsights Unleashed podcast to uncover global healthcare trends and empower patients with valuable insights.